Blincyto OverviewBlinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014 it was approve...
Read more Blincyto Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Blinatumomab
Recent Blincyto Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 35mcg
NDC Database Records for Blincyto: (1 result)Sorted by National Drug Code
- 55513-160 Blincyto Intravenous Kit by Amgen Inc